Browsing Tag
Johnson & Johnson
102 posts
Wall Street reacts as Johnson & Johnson circles Protagonist Therapeutics in a potential multibillion-dollar buyout
Explore how Johnson & Johnson’s bid to acquire Protagonist Therapeutics could reshape its immunology and hematology pipeline—details inside.
Johnson & Johnson (NYSE: JNJ) gains FDA approval to expand SIMPONI into pediatric ulcerative colitis
FDA approves SIMPONI (golimumab) for children ≥15 kg with ulcerative colitis, expanding Johnson & Johnson’s immunology portfolio. Learn what it means for patients.
Inside Johnson & Johnson’s $966m talc verdict: how one case could reshape its future battles
Find out how Johnson & Johnson’s $966 million talc cancer verdict could reshape its litigation strategy, investor sentiment, and brand credibility.
Johnson & Johnson wins FDA approval for Tremfya in pediatric psoriasis and psoriatic arthritis
Johnson & Johnson wins FDA approval for Tremfya in pediatric psoriasis and psoriatic arthritis, extending its immunology lead and boosting growth prospects.
Can immune-based doublets push CAR-T and bispecifics into earlier multiple myeloma treatment lines?
Can immune-based doublets like TECVAYLI and DARZALEX FASPRO push CAR-T and bispecifics into earlier multiple myeloma treatment lines?
AusperBio raises $63mn series B2 round to advance AHB-137 and expand global hepatitis B
AusperBio raises $63M Series B2 funding to advance AHB-137 pivotal trials, expand its Med-Oligo platform, and reshape the hepatitis B cure race.
Can Johnson & Johnson’s TECVAYLI and DARZALEX FASPRO regimen redefine first-line multiple myeloma treatment?
Johnson & Johnson’s TECVAYLI + DARZALEX FASPRO combo hit 100% MRD negativity in new myeloma trial. Can this immune-based regimen redefine frontline care?
Johnson & Johnson (NYSE: JNJ) wins key CHMP backing for nipocalimab in gMG—could this reshape Europe’s autoimmune treatment market?
Johnson & Johnson’s nipocalimab wins CHMP backing for gMG, setting stage for potential EU approval in adults and adolescents. Learn what this means for patients.
Why Henlius Biotech’s HLX43 deal talks with Johnson & Johnson and Roche are shaking up global oncology
Henlius Biotech is negotiating with Johnson & Johnson and Roche on HLX43 rights. Learn how this deal could reshape oncology licensing and investor sentiment.
Why are activist hedge funds circling Kenvue and what does Sachem Head’s entry signal for investors?
Activist hedge funds including Sachem Head are circling Kenvue. Find out what’s driving the pressure and what it means for investors.